Expression and Role of STK11 protein in Cervical Cancer
DOI:
https://doi.org/10.54097/n5n2zx15Keywords:
STK11, Cervical Cancer, Express, RoleAbstract
Objective: This study explores STK11 expression and mechanism in cervical cancer tissue. Methods: STK11 expression in cervical cancer was retrieved from Xiantao Academic Database and The Human Protein Atlas. UALCAN was used to analyze its correlation with patients' pathological characteristics. KM Plotter provided gene expression data and survival statistics for cervical cancer, which underwent COX regression to determine STK11 expression's relationship with overall survival and calculate patients' risk ratio. TIMER was used to investigate associations between STK11 expression and immune cell infiltration in cervical cancer. STRING constructed the STK11-related protein-protein interaction network. Finally, immunohistochemistry verified STK11 protein expression in 90 cervical cancer tissues and 26 adjacent tissues, analyzing correlations with prognosis and clinical characteristics. Results: STK11 protein expression was significantly lower in cervical cancer tissue than normal cervical tissue, correlating with recurrence (P < 0.05) but not with overall survival, age, cancer type, clinical stage, pathological grade, or lymphatic metastasis (P > 0.05). Additionally, STK11 expression in cervical cancer positively correlated with B cell and CD4+ T cell infiltration (P < 0.05). Conclusion: Low STK11 protein expression in cervical cancer associates with disease occurrence and development, potentially serving as an early diagnostic indicator and novel therapeutic target for cervical cancer.
Downloads
References
[1] SUNG H, ERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–49.
[2] ARBYN M, WEIDERPASS E, BRUNi L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020;8: e191–203.
[3] FOWLER J R, MAANI E V, JACK B W. Cervical Cancer[M]. Treasure Island(FL):StatPearls Publishing, 2021.
[4] WARD ZJ, SCOTT AM, HRICAK H, et al. Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis. Lancet Oncol. 2021; 22:341–50.
[5] LADERIAN B, MUNDI P, FOJO T, et al. Emerging Therapeutic Implications of STK11 Mutation: Case Series [J]. Oncologist, 2020,25(9): 733-737.
[6] LATTOUF H, KASSEM L, JACQUEMETTON J, et al. LKB1 regulates PRMT5 activity in breast cancer [J]. Int J Cancer, 2019,144(3): 595-606.
[7] HIROSE S, MURAKAMI N, TAKAHASHI K, et al. Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients [J]. Gynecol Oncol, 2020,156(1): 203-210.
[8] LI X, ZHANG Y, CAO S, et al. Reduction of TIP30 correlates with poor prognosis of gastric cancer patients and its restoration drastically inhibits tumor growth and metastasis [J]. Int J Cancer, 2009,124(3): 713-721.
[9] SHACKELFORD D B, SHAW R J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression [J]. Nat Rev Cancer, 2009,9(8): 563-575.
[10] HEMMINKI A. The molecular basis and clinical aspects of Peutz-Jeghers syndrome [J]. Cell Mol Life Sci, 1999,55(5): 735-750.
[11] SYNGAL S, BRAND R E, CHURCH J M, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes [J]. Am J Gastroenterol, 2015,110(2): 223-262, 263.
[12] XIAO J, ZOU Y, CHEN X, et al. The Prognostic Value of Decreased LKB1 in Solid Tumors: A Meta-Analysis [J]. PLoS One, 2016,11(4): e152674.
[13] SPRANGER S, GAJEWSKI T F. Impact of oncogenic pathways on evasion of antitumour immune responses [J]. Nat Rev Cancer, 2018,18(3): 139-147.
[14] KOYAMA S, AKBAY E A, LI Y Y, et al. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment[J]. Cancer Res, 2016,76(5): 999-1008.
[15] LIU R, QIAN M, ZHOU T, et al. TP53 mediated miR-3647-5p prevents progression of cervical carcinoma by targeting AGR2 [J]. Cancer Med, 2019,8(13): 6095-6105.
[16] Li ZQ, Wang LD, Yan XH. Expression characteristics and clinical significance of CTNNB1 and TP53 in cervical cancer tissues. J Clin Exp Med. 2020;19(10):1081-1085.
[17] BANGE E, MARMARELIS M E, HWANG W T, et al. Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer[J]. JCO Precis Oncol, 2019(3).
[18] Zhang MN, Zhang H, Zhang J, et al. miR-451a overexpression impacts cervical cancer cell proliferation and apoptosis via molecular mechanisms. J Shanxi Med Univ. 2017;48 (11): 1145-1148.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
